ABBV-291 / AbbVie - LARVOL DELTA

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=165 | Recruiting | Sponsor: AbbVie | Trial primary completion date: Nov 2031 ➔ Jan 2027

Adverse events • First-in-human • Monotherapy • Trial primary completion date • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A PHASE 1 STUDY EVALUATING SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV-291, A CD79B-TARGETING ADC IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (ICML 2025) - P1 | "PK parameters are determined using noncompartmental methods. The study is actively enrolling globally."

Clinical • IO biomarker • P1 data • PK/PD data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD79B

A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. (ASCO 2025) - P1 | "PK parameters are determined using noncompartmental methods. The study is actively enrolling globally."

Clinical • IO biomarker • P1 data • PK/PD data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • CD79B

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio (PRNewswire) - "AbbVie...announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3, 2025). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers."

Clinical data • B Cell Non-Hodgkin Lymphoma • Castration-Resistant Prostate Cancer • Prostate Cancer • Urothelial Cancer